Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea · Delayed Price · Currency is KRW 88,200
+1,600 (1.85%)
At close: Dec 11, 2025
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 429.82B KRW in the quarter ending September 30, 2025, with 4.13% growth. This brings the company's revenue in the last twelve months to 1.68T, up 0.32% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.
Revenue (ttm)
1.68T
Revenue Growth
+0.32%
P/S Ratio
0.68
Revenue / Employee
746.11M
Employees
2,253
Market Cap
1.14T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.59T | -82.97B | -4.97% |
| Dec 31, 2023 | 1.67T | 181.06B | 12.17% |
| Dec 31, 2022 | 1.49T | 144.79B | 10.78% |
| Dec 31, 2021 | 1.34T | 40.55B | 3.11% |
| Dec 31, 2020 | 1.30T | 223.67B | 20.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |